A private company, China Ophthalmology Focus Ltd., founded in 2018 and located in Honk Kong has recently raised $50 million in a series A round… Read More »A private company, China Ophthalmology Focus Ltd, is set to focus on the ophthalmic Asia market.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the winners of the seventh annual Regeneron Prize for Creative Innovation. The country’s leading research universities were asked to… Read More »Regeneron Pharmaceuticals Inc. announces the 2019 winners of the “Regeneron Prize for Creative Innovation”
Oxford Biomedica plc (LSE:OXB) and Santen Pharmaceutical Co., Ltd. (Santen) have entered into an R&D collaboration with an option and licence agreement to develop gene… Read More »Oxford Biomedica executes an option and license agreement for gene therapy for inherited retinal disease
Alkahest Inc., a clinical stage biopharmaceutical company based in San Carlos, California, has announced that an experimental drug, AKST4290, in a Phase IIa study for… Read More »Alkahest’s oral small molecule drug aims to report on a Phase IIa study for age-related macular degeneration
The following two biomedical companies – Gyroscope Therapeutics in Stevenage UK and Orbit Biomedical in Philadelphia, US – have announced that they have merged in… Read More »Gyroscope Therapeutics and Orbit Biomedical have merged into a new retinal gene therapy company
Global news reports have highlighted a lawsuit in 44 states in the US for price-fixing and collusion among several large pharmaceutical companies. Following for the… Read More »Drug companies sued in multiple States over price-fixing of generic drugs, several leading up to 1,000% increase of cost to patients
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), have announced a collaboration to “discover, develop and commercialize new RNA interference (RNAi) therapeutics for… Read More »Alnylam Pharmaceuticals, Inc. and Regeneron Pharmaceuticals, Inc. have established a new RNAi collaboration for the development of ocular and CNS treatments
Nightstar Therapeutics plc,. (NASDAQ: NITE), has reported that an acquisition agreement with Biogen is to be completed in mid-year 2019 for an estimated $877M. Nightstar… Read More »Nightstar Therapeutics plc (Waltham, Mass. and London) is acquired by Biogen (Switzerland) for an estimated $877M
Spark Therapeutics Inc,. has reported that a definitive merger agreement with Roche to acquire Spark at a price of $114.50 per share in an all-cash… Read More »Spark Therapeutics (NASDAQ: ONCE) confirms that a definitive agreement will merge with Roche
Research published by several investigators in UK universities, including York University, King’s College, London and Queen Mary University, London, states that “the uncertainty of a… Read More »A “no deal” Brexit scenario may start a domino effect for a “collapse” in the UK pharmaceutical industry